Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Overview

The primary objective of this single-center multi-site retrospective chart review is to determine if paliperidone palmitate and/or risperidone long-acting injection can decrease the number of psychiatric relapses following their initiation in an inpatient acute psychiatric unit compared to oral antipsychotic therapy and determine if one treatment is superior to the other in this regard. This study will utilize a mirror-image design and incorporate up to a 3 years of follow-up following the index admission. Secondary objectives of this study will be to determine the change in hospital resource utilization for psychiatric reasons following treatment initiation, and to determine the difference in time to relapse.

Full Title of Study: “Mirror-image Study Exploring Relapse and Resource Utilization of Paliperidone Palmitate and Risperidone Long-acting Injection in Vitalité Health Network Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 2018

Interventions

  • Drug: Paliperidone Palmitate
    • Monthly injections
  • Drug: Risperidal Consta
    • Bi-weekly injection
  • Drug: Antipsychotic
    • Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.

Arms, Groups and Cohorts

  • Paliperidone Palmitate
    • Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
  • Risperidone Long-acting injection.
    • Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.

Clinical Trial Outcome Measures

Primary Measures

  • Psychiatric Relapse
    • Time Frame: up to 3 years
    • Hospitalizations will be used as a proxy for relapse and the primary endpoint will be the number of hospital admissions following the discharge date of the index admission for up to 3 years compared to an equivalent timeframe prior to the beginning of the index admission (and including the 1st day of the index admission). Patients will be considered eligible for the primary objective after 3 months of continued long-acting injection treatment.

Secondary Measures

  • Hospital Resource utilization for psychiatric reasons
    • Time Frame: up to 3 years
    • Number of ER visits for psychiatric reasons, number of days admitted in hospital for psychiatric reasons.
  • Time to relapse
    • Time Frame: up to 3 years
    • time following discharge of index admission until the subsequent admission for psychiatric reasons (in days); time following discharge of index admission until the subsequent ER visit for psychiatric reasons (in days).

Participating in This Clinical Trial

Inclusion Criteria

• Patients who were initiated on either Risperidone long-acting injection or Paliperidone palmitate during an acute psychiatric admission for schizophrenia or other psychotic related disorders. Exclusion Criteria:

  • Patients who had their long-acting injection stopped prior to the discharge date of their index admission. – Patients who received a long-acting injection in the year prior to the index admission. – Patients who had a psychiatric admission to a forensic, rehabilitation or high dependency unit during the observation period prior to or following their index admission.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Investigator Details

  • Lead Sponsor
    • Réseau de Santé Vitalité Health Network
  • Collaborator
    • Janssen Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Michael Kemp, Psychiatric Pharmacist and Clinical Researcher – Réseau de Santé Vitalité Health Network

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.